FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 70 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 January 15, 2021 Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:... February 8, 2021 A College Senior vs. A Global Pandemic September 30, 2020 FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... February 21, 2025 Load more HOT NEWS Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced... Immune cell count could determine whether chemotherapy is required in oropharyngeal... Resource Round-Up: Let’s Win Pancreatic Cancer Long-Term Responders with No Evidence of Disease Have Better Survival to...
